2022 ASCO Annual Meeting: Targeted Therapy for Advanced HR-Positive, HER2-Negative Breast Cancer and Using Liquid Biopsy to Guide Treatment for Stage II Colon Cancer
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include targeted therapy for advanced hormone receptor-positive, HER2-negative breast cancer and using liquid biopsy to guide post-surgery treatment decisions for stage II colon cancer.